We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+7.19%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$811M
AUM Growth
+$71.2M
Cap. Flow
+$48M
Cap. Flow %
5.92%
Top 10 Hldgs %
28.89%
Holding
102
New
7
Increased
37
Reduced
34
Closed
10

Top Buys

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$18.2M
2
BDX icon
Becton Dickinson
BDX
+$16.8M
3
BMY icon
Bristol-Myers Squibb
BMY
+$14.2M
4
CELG
Celgene Corp
CELG
+$13M
5
CI icon
Cigna
CI
+$12.6M

Top Sells

Rank Stock Value
1
ADMS
Adamas Pharmaceuticals
ADMS
+$15.2M
2
NKTR icon
Nektar Therapeutics
NKTR
+$12.5M
3
ESPR
Esperion Therapeutics
ESPR
+$10.4M
4
COR icon
Cencora
COR
+$6.72M
5
UHS icon
Universal Health Services
UHS
+$5.94M

Sector Composition

Rank Sector Weight
1 Healthcare 94.68%
2 Technology 0.23%
3 Energy 0.22%
4 Financials 0.18%
5 Consumer Discretionary 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HAL icon
76
Halliburton
HAL
$27.8B
$688K 0.08%
14,659
+3,515
+32% +$173K
XOM icon
77
ExxonMobil
XOM
$656B
$636K 0.08%
8,526
+2,830
+50% +$226K
JPM icon
78
JPMorgan Chase
JPM
$955B
$593K 0.07%
5,391
+873
+19% +$98.8K
JHG
79
DELISTED
Janus Henderson
JHG
$591K 0.07%
17,859
+5,953
+50% +$219K
IBM icon
80
IBM
IBM
$224B
$579K 0.07%
3,947
+2,100
+114% +$318K
MSFT icon
81
Microsoft
MSFT
$3.78T
$499K 0.06%
5,465
+672
+14% +$61.5K
CVX icon
82
Chevron
CVX
$379B
$473K 0.06%
+4,148
New +$496K
F icon
83
Ford
F
$55.7B
$472K 0.06%
42,606
+14,202
+50% +$160K
BUD icon
84
AB InBev
BUD
$164B
$463K 0.06%
4,209
+1,403
+50% +$156K
DIS icon
85
Walt Disney
DIS
$178B
$463K 0.06%
+4,613
New +$490K
QCOM icon
86
Qualcomm
QCOM
$172B
$446K 0.06%
8,052
+2,684
+50% +$171K
STAA icon
87
STAAR Surgical
STAA
$1.25B
$365K 0.05%
24,658
-51,598
-68% -$806K
GEN icon
88
Gen Digital
GEN
$17.6B
$363K 0.04%
14,039
+4,680
+50% +$127K
RGLS
89
DELISTED
Regulus Therapeutics
RGLS
$354K 0.04%
4,107
– –
PFE icon
90
Pfizer
PFE
$154B
$311K 0.04%
9,227
-1,758
-16% -$60.4K
WFC icon
91
Wells Fargo
WFC
$265B
$307K 0.04%
5,858
-1,777
-23% -$106K
RARX
92
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$208K 0.03%
39,115
-69,336
-64% -$496K
DVAX
93
DELISTED
Dynavax Technologies
DVAX
– –
-242,812
Closed -$4.54M
DXCM icon
94
DexCom
DXCM
$33B
– –
-282,500
Closed -$4.05M
HCA icon
95
HCA Healthcare
HCA
$89.8B
– –
-58,886
Closed -$5.17M
PBYI icon
96
Puma Biotechnology
PBYI
$448M
– –
-50,000
Closed -$4.94M
RARE icon
97
Ultragenyx Pharmaceutical
RARE
$2.6B
– –
-95,000
Closed -$4.41M
UHS icon
98
Universal Health Services
UHS
$10.5B
– –
-52,433
Closed -$5.94M
NVRO
99
DELISTED
NEVRO CORP.
NVRO
– –
-15,145
Closed -$1.05M
ICPT
100
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-38,500
Closed -$2.25M
1 2 3
4
5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2018 Portfolio in Review

As of Q1 2018, Rhenman & Partners Asset Management held 102 positions worth $811M, up 9.6% from $740M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management deployed $48M of net new capital in Q1 2018, opening 7 new positions and adding to 37 existing holdings. Its largest new stake was CVS Health: 253,868 shares worth $15.8M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 90% a quarter earlier, followed by Technology and Energy.

On the sell side, the largest reduction was Adamas Pharmaceuticals, an estimated $15.2M trimmed.

  • Rhenman & Partners Asset Management's largest Q1 2018 buy was CVS Health: 253,868 shares worth $15.8M.
  • Rhenman & Partners Asset Management added most to Bristol-Myers Squibb in Q1 2018, an estimated $14.2M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2018 reduction was Adamas Pharmaceuticals, cutting an estimated $15.2M.
  • Rhenman & Partners Asset Management fully exited Universal Health Services in Q1 2018, selling an estimated $5.94M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $811M portfolio in Q1 2018.
  • Rhenman & Partners Asset Management opened 7 new positions and closed 10 in Q1 2018.
  • Rhenman & Partners Asset Management's portfolio value rose 9.6% quarter-over-quarter to $811M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2018, filed 11 Apr 2018.